未登录

R

Ross B. Fulton

merrimack pharmaceuticals, inc.

H指数:13

被引数:952

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

FRONTIERS IN ONCOLOGY

IF3.3

2022-05-2611

OAAI

CD8+ T cell self-tolerance permits responsiveness but limits tissue damage

IF0

2021-04-308

OA

HFB10-1E1, a novel OX-40 agonistic antibody with a unique pharmacological profile and biomarker strategy

CANCER RESEARCH

IF16.6

2020-08-150

PRE

Synergy between EphA2-ILs-DTXp, a Novel EphA2-Targeted Nanoliposomal Taxane, and PD-1 Inhibitors in Preclinical Tumor Models

MOLECULAR CANCER THERAPEUTICS

IF5.5

2020-01-0321

OAAI

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

SCIENCE TRANSLATIONAL MEDICINE

IF14.6

2019-10-0248

OAAI

Tam, Eric M.; Fulton, Ross B.; Sampson, James F.; Muda, Marco; Camblin, Adam; Richards, Jennifer; Koshkaryev, Alexander; Tang, Jian; Kurella, Vinodh; Jiao, Yang; Xu, Lihui; Zhang, Kathy; Kohli, Neeraj; Luus, Lia; Hutto, Elizabeth; Kumar, Sandeep; Lulo, James; Paragas, Violette; Wong, Christina; Suchy, James; Grabow, Stephanie; Dugast, Anne-Sophie; Zhang, Hong; Depis, Fabien; Feau, Sonia; Jakubowski, Aniela; Qiao, Wenlian; Craig, Galina; Razlog, Maja; Qiu, James; Zhou, Yu; Marks, James D.; Croft, Michael; Drummond, Daryl C.; Raue, Andreas

Mechanism of action of a novel agonist TNFR2 antibody that induces co-stimulation of T cells and promotes robust anti-tumor immunity

CANCER RESEARCH

IF16.6

2019-07-012

PRE

MM-401, a novel anti-TNFR2 antibody that induces T cell co-stimulation, robust anti-tumor activity and immune memory

CANCER RESEARCH

IF16.6

2019-07-017

PRE

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

JOURNAL OF IMMUNOLOGY

IF3.4

2019-05-1512

OAAI

Imprime PGG, a soluble yeast b-glucan PAMP, enhancement of anti-tumor responses in combination with tumor targeting antibody is highly dependent on NK cell killing

CANCER RESEARCH

IF16.6

2018-07-011

PRE

Imprime PGG, a soluble yeast b-glucan PAMP, activates both innate and adaptive immune effector cells, resulting in enhanced antitumor responses that synergize with anti-PD-1 antibody therapy

MOLECULAR CANCER THERAPEUTICS

IF5.5

2018-01-011

PRE

Imprime PGG modulates immunosuppressive myeloid components of the tumor microenvironment and drives enhanced antitumor efficacy in combination with checkpoint inhibitor therapies

CANCER RESEARCH

IF16.6

2017-07-012

PRE

A novel tumor vaccine platform: direct conjugation of antigens to the β glucan PAMP Imprime PGG enhances antigen presentation and T cell priming

CANCER RESEARCH

IF16.6

2017-07-010

PRE

Imprime PGG, a yeast β-glucan PAMP, induces a unique cytokine profile and enhances immune checkpoint inhibitor therapy

EUROPEAN JOURNAL OF CANCER

IF7.1

2016-12-011

PREAI

Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

CANCER RESEARCH

IF16.6

2016-07-151

PRE

Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern) activates the direct killing functions of innate immune cells in concert with tumor targeting antibodies

CANCER RESEARCH

IF16.6

2016-07-151

PRE

Imprime PGG drives adaptive immune resistance within the tumor microenvironment by modulating the myeloid compartment and enhances the efficacy of anti-PD1 antibody in vivo

CANCER RESEARCH

IF16.6

2016-07-151

PRE

Imprime PGG triggers PD-L1 expression on tumor and myeloid cells and prevents tumor establishment in combination with aPD-L1 treatment in vivo

CANCER RESEARCH

IF16.6

2016-07-155

PRE

Imprime PGG conjugated directly to protein enables cross-presentation of antigen that generates multifunctional cytotoxic T cells

CANCER RESEARCH

IF16.6

2015-08-010

PRE

Imprime PGG decreases regulatory T cell suppression and enhances T cell proliferation and differentiation revealing additional mechanisms for its anti-tumor activity

CANCER RESEARCH

IF16.6

2015-08-015

PRE

The TCR's sensitivity to self peptide-MHC dictates the ability of naive CD8+ T cells to respond to foreign antigens

NATURE IMMUNOLOGY

IF27.6

2014-11-24182

OAAI